VAR2 Pharmaceuticals management team expands with experienced drug development COO

As of May 1st,  Dr. Andreas L Norlin has taken up the position as Chief Operating Officer. Andreas comes with a deep knowledge of drug development strategy and execution from more than 20 years in research, pre-clinical and clinical development in academia, biotech and big pharma, most recently as global project leader at Novo Nordisk A/S. The combination of the experience of leading drug development projects, general business and commercialisation understanding, insights in regulatory requirements and involvement in multiple in-/out-licensing activities will become a significant asset in driving the VAR2 platform towards clinical development and commercialisation.